Terug
28
Dagbereik
€ 132,88
€ 142,11
52-Weeksbereik
€ 121,06
€ 359,97
Volume
1.497.320
50D / 200D Gem.
€ 160,65
/
€ 181,77
Vorige Slotkoers
€ 135,24
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 15,5 | 0,3 |
| P/B | 1,8 | 2,9 |
| ROE % | 11,0 | 3,7 |
| Net Margin % | 1,0 | 3,8 |
| Rev Growth 5Y % | 13,1 | 10,0 |
| D/E | 1,0 | 0,2 |
Koersdoel Analisten
Hold
€ 175,64
+23.9%
Low: € 124,00
High: € 310,00
Forward K/W
26,8
Forward WPA
€ 5,04
WPA Groei (sch.)
+0,0%
Omzet Sch.
45 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 25,38
€ 23,65 – € 27,55
|
53 B | 2 |
| FY2029 |
€ 19,10
€ 17,80 – € 20,73
|
50 B | 2 |
| FY2028 |
€ 12,34
€ 10,37 – € 13,34
|
49 B | 4 |
Belangrijkste Punten
Revenue grew 13,09% annually over 5 years — strong growth
Earnings declined -59,97% over the past year
ROE of 11,02% — decent returns on equity
Negative free cash flow of -636,00M
Capital efficient — spends only 0,22% of revenue on capex
Groei
Revenue Growth (5Y)
13,09%
Revenue (1Y)11,75%
Earnings (1Y)-59,97%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
11,02%
ROIC7,30%
Net Margin1,04%
Op. Margin1,72%
Veiligheid
Debt / Equity
0,97
Current Ratio1,69
Interest Coverage4,07
Waardering
P/E Ratio
15,47
P/B Ratio1,79
EV/EBITDA8,96
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11,75% | Revenue Growth (3Y) | 15,47% |
| Earnings Growth (1Y) | -59,97% | Earnings Growth (3Y) | -34,23% |
| Revenue Growth (5Y) | 13,09% | Earnings Growth (5Y) | -8,01% |
| Profitability | |||
| Revenue (TTM) | 45,43B | Net Income (TTM) | 472,00M |
| ROE | 11,02% | ROA | 3,03% |
| Gross Margin | 8,97% | Operating Margin | 1,72% |
| Net Margin | 1,04% | Free Cash Flow (TTM) | -636,00M |
| ROIC | 7,30% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,97 | Current Ratio | 1,69 |
| Interest Coverage | 4,07 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 15,47 | P/B Ratio | 1,79 |
| P/S Ratio | 0,16 | PEG Ratio | -0,33 |
| EV/EBITDA | 8,96 | Dividend Yield | 0,00% |
| Market Cap | 7,30B | Enterprise Value | 7,00B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 45,43B | 40,65B | 34,07B | 31,97B | 27,77B |
| Net Income | 472,00M | 1,18B | 1,09B | 792,00M | 659,00M |
| EPS (Diluted) | 8,92 | 20,42 | 18,78 | 13,54 | 11,25 |
| Gross Profit | 4,08B | 4,74B | 4,33B | 3,93B | 3,28B |
| Operating Income | 781,00M | 1,71B | 1,57B | 1,17B | 1,02B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 15,56B | 15,63B | 14,89B | 12,31B | 12,21B |
| Total Liabilities | 11,50B | 11,13B | 10,68B | 9,35B | 9,58B |
| Shareholders' Equity | 4,07B | 4,50B | 4,22B | 2,96B | 2,63B |
| Total Debt | 3,95B | 3,12B | 2,39B | 2,39B | 2,39B |
| Cash & Equivalents | 4,25B | 4,66B | 4,85B | 4,01B | 4,44B |
| Current Assets | 12,44B | 12,77B | 12,54B | 10,08B | 10,06B |
| Current Liabilities | 7,37B | 7,90B | 8,17B | 6,86B | 7,05B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#382 of 618
Recente Activiteit
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026